retreatment with pegylated interferon alpha-2a and ribavirin in patients with chronic hepatitis c who have relapsed or not responded to a first course of pegylated interferon-based therapy

Clicks: 230
ID: 210278
2009
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #39 of 250 articles by views in indian journal of pharmacology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 250 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Pegylated interferon (pegIFN) and ribavirin combination therapy remains the first-line treatment for chronic hepatitis C virus (HCV) infection. In contrast to the wealth of studies in treatment-naive patients, the effectiveness of retreatment in patients who have previously failed pegIFN-based therapy is largely unreported.
Reference Key
yoshida2009canadianretreatment Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Eric M Yoshida;Morris Sherman;Vincent G Bain;Curtis L Cooper;Marc Deschênes;Paul J Marotta;Samuel S Lee;Mel Krajden;Helga Witt-Sullivan;Robert J Bailey;Christopher Usaty;Kevork Peltekian;the Canadian Pegasys Study Group
Journal indian journal of pharmacology
Year 2009
DOI
10.1155/2009/470532
URL
http://dx.doi.org/10.1155/2009/470532
Keywords
Gastroenterology diseases of the digestive system

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.